Cargando…

Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization

BACKGROUND: The estrogen metabolite 2-methoxyestradiol (2ME2) and a number of synthesised derivatives have been shown to bind to microtubules thereby arresting cancer cells in mitosis which leads to apoptosis. In interphase cells, microtubules play an important role in the delivery of proteins to su...

Descripción completa

Detalles Bibliográficos
Autores principales: van Vuuren, Rustelle Janse, Botes, Mandie, Jurgens, Tamarin, Joubert, Anna Margaretha, van den Bout, Iman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317210/
https://www.ncbi.nlm.nih.gov/pubmed/30622437
http://dx.doi.org/10.1186/s12935-018-0719-4
_version_ 1783384707184984064
author van Vuuren, Rustelle Janse
Botes, Mandie
Jurgens, Tamarin
Joubert, Anna Margaretha
van den Bout, Iman
author_facet van Vuuren, Rustelle Janse
Botes, Mandie
Jurgens, Tamarin
Joubert, Anna Margaretha
van den Bout, Iman
author_sort van Vuuren, Rustelle Janse
collection PubMed
description BACKGROUND: The estrogen metabolite 2-methoxyestradiol (2ME2) and a number of synthesised derivatives have been shown to bind to microtubules thereby arresting cancer cells in mitosis which leads to apoptosis. In interphase cells, microtubules play an important role in the delivery of proteins to subcellular locations including the focal adhesions. In fact, focal adhesion dynamics and cell migration are in part regulated by microtubules. We hypothesised that novel 2ME2 derivatives can alter cell migration by influencing microtubule dynamics in interphase cells. In this report we describe 2ME2 derivatives that display anti-migratory capabilities in a metastatic breast cancer cell line through their effects on the microtubule network resulting in altered focal adhesion signalling and RhoA activity. METHODS: Cell migration was assayed using wound healing assays. To eliminate mitosis blockage and cell rounding as a confounding factor cell migration was also assessed in interphase blocked cells. Fluorescence confocal microscopy was used to visualise microtubule dynamics and actin cytoskeleton organisation while western blot analysis was performed to analyse focal adhesion signalling and RhoA activation. RESULTS: 2ME2 derivatives, ESE-one and ESE-15-one, inhibited cell migration in cycling cells as expected but equally diminished migration in cells blocked in interphase. While no significant effects were observed on the actin cytoskeleton, focal adhesion kinase activity was increased while RhoA GTPase activity was inhibited after exposure to either compound. Microtubule stability was increased as evidenced by the increased length and number of detyrosinated microtubules while at the same time clear disorganisation of the normal radial microtubule organisation was observed including multiple foci. CONCLUSIONS: ESE-15-one and ESE-one are potent migration inhibitors of metastatic breast cancer cells. This ability is coupled to alterations in focal adhesion signalling but more importantly is associated with severe disorganisation of microtubule dynamics and polarity. Therefore, these compounds may offer potential as anti-metastatic therapies.
format Online
Article
Text
id pubmed-6317210
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63172102019-01-08 Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization van Vuuren, Rustelle Janse Botes, Mandie Jurgens, Tamarin Joubert, Anna Margaretha van den Bout, Iman Cancer Cell Int Primary Research BACKGROUND: The estrogen metabolite 2-methoxyestradiol (2ME2) and a number of synthesised derivatives have been shown to bind to microtubules thereby arresting cancer cells in mitosis which leads to apoptosis. In interphase cells, microtubules play an important role in the delivery of proteins to subcellular locations including the focal adhesions. In fact, focal adhesion dynamics and cell migration are in part regulated by microtubules. We hypothesised that novel 2ME2 derivatives can alter cell migration by influencing microtubule dynamics in interphase cells. In this report we describe 2ME2 derivatives that display anti-migratory capabilities in a metastatic breast cancer cell line through their effects on the microtubule network resulting in altered focal adhesion signalling and RhoA activity. METHODS: Cell migration was assayed using wound healing assays. To eliminate mitosis blockage and cell rounding as a confounding factor cell migration was also assessed in interphase blocked cells. Fluorescence confocal microscopy was used to visualise microtubule dynamics and actin cytoskeleton organisation while western blot analysis was performed to analyse focal adhesion signalling and RhoA activation. RESULTS: 2ME2 derivatives, ESE-one and ESE-15-one, inhibited cell migration in cycling cells as expected but equally diminished migration in cells blocked in interphase. While no significant effects were observed on the actin cytoskeleton, focal adhesion kinase activity was increased while RhoA GTPase activity was inhibited after exposure to either compound. Microtubule stability was increased as evidenced by the increased length and number of detyrosinated microtubules while at the same time clear disorganisation of the normal radial microtubule organisation was observed including multiple foci. CONCLUSIONS: ESE-15-one and ESE-one are potent migration inhibitors of metastatic breast cancer cells. This ability is coupled to alterations in focal adhesion signalling but more importantly is associated with severe disorganisation of microtubule dynamics and polarity. Therefore, these compounds may offer potential as anti-metastatic therapies. BioMed Central 2019-01-03 /pmc/articles/PMC6317210/ /pubmed/30622437 http://dx.doi.org/10.1186/s12935-018-0719-4 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated.
spellingShingle Primary Research
van Vuuren, Rustelle Janse
Botes, Mandie
Jurgens, Tamarin
Joubert, Anna Margaretha
van den Bout, Iman
Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization
title Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization
title_full Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization
title_fullStr Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization
title_full_unstemmed Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization
title_short Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization
title_sort novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317210/
https://www.ncbi.nlm.nih.gov/pubmed/30622437
http://dx.doi.org/10.1186/s12935-018-0719-4
work_keys_str_mv AT vanvuurenrustellejanse novelsulphamoylated2methoxyestradiolderivativesinhibitbreastcancermigrationbydisruptingmicrotubuleturnoverandorganization
AT botesmandie novelsulphamoylated2methoxyestradiolderivativesinhibitbreastcancermigrationbydisruptingmicrotubuleturnoverandorganization
AT jurgenstamarin novelsulphamoylated2methoxyestradiolderivativesinhibitbreastcancermigrationbydisruptingmicrotubuleturnoverandorganization
AT joubertannamargaretha novelsulphamoylated2methoxyestradiolderivativesinhibitbreastcancermigrationbydisruptingmicrotubuleturnoverandorganization
AT vandenboutiman novelsulphamoylated2methoxyestradiolderivativesinhibitbreastcancermigrationbydisruptingmicrotubuleturnoverandorganization